Please login to the form below

Not currently logged in
Email:
Password:

Columbia Laboratories retires all debt

Columbia Laboratories has sold its progesterone-related assets and 11.2m shares of common stock to Watson Pharmaceuticals to become debt-free
Columbia Laboratories has closed the sale of its progesterone-related assets and 11.2m shares of common stock to Watson Pharmaceuticals and is debt-free, the company has announced. Columbia now has over $25m in cash and approximately 84 million common shares outstanding.

The company received $47m in cash from Watson; Watson also forgave the interest on a $15m loan it had given Columbia on June 1, 2010. Columbia used approximately $16m of the initial proceeds to pre-pay the balance of the minimum royalty payments due in November 2010 to PharmaBio Development, and $26m, together with stock and warrants, to pre-pay the entire balance of the $40m in convertible notes due by December 31, 2011.

Becoming debt-free has improved the company's outlook significantly, according to Frank C Condella, Jr, president and chief executive officer of Columbia. 

"In the near term, Columbia will focus on the smooth transfer of domestic commercial operations for Crinone 8 per cent (progesterone gel) to Watson, completing the PREGNANT study of Prochieve 8 per cent (progesterone gel), and developing with Watson the next generation progesterone product," he said in a statement. 

The PREGNANT study is a randomised, double-blind, placebo controlled phase III trial to evaluate the safety and efficacy of Prochieve to reduce the risk of preterm birth in women with a cervical length between 1.0cm and 2.0cm as measured by transvaginal ultrasound at mid-pregnancy. 

Columbia's business now consists of its royalty and manufacturing revenues, potential milestone payments, its collaboration with Watson on the development of next-generation progesterone products and its novel bioadhesive drug delivery technologies and other products. Columbia retains all rights necessary to perform its obligations under its agreement with Merck Serono, which relates to sales of Crinone (progesterone gel) outside the US.

8th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics